PCI for Intratumoral Immunotherapy
Oncology (overcoming checkpoint inhibitor resistance)
ExploratoryTerminated (Liquidation)
Key Facts
Indication
Oncology (overcoming checkpoint inhibitor resistance)
Phase
Exploratory
Status
Terminated (Liquidation)
Company
About PCI Biotech
PCI Biotech leveraged its photochemical technology platform, originating from research at Oslo University Hospital, to address key challenges in drug delivery and biomanufacturing. The company focused on two main applications: PCI for enhancing the intracellular delivery of therapeutics in oncology and dermatology, and PCL for improving yield and purity in viral vector manufacturing for gene therapies. Despite reaching preclinical and early clinical stages with its technologies, the company's shareholders resolved to dissolve and delist the company in 2026, ceasing its development activities.
View full company profile